Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Edscharp who wrote (9986)	5/16/1999 1:03:00 AM
From: aknahow	Read Replies (3) \| Respond to of 17367

Off label use can and will occur. Xoma will not be able to promote it. As it occurs and independent research indicates value for other indications Xoma will be able to distribute this information to potential decision makers. This is my understanding, of how off label use will occur and the eventual impact of such use. I would not however expect this to happen all that quickly. But considering all the doctors involved in the Meningococcemia trials, if Neuprex really works, and they have see kids that might have died perhaps the incentive to try BPI on other indications will be great. Sorry to talk out of both sides of my mouth.